![ASCO 2022 Conference Coverage](http://media.vumedi.com/thumbs/channel_logo/2022/5/eadfa937-de35-4504-be38-58654669525f.png.200x0_q85.png)
ASCO 2022 Conference Coverage
Lecture Summary - ASCO 2022 on Perioperative Ramucirumab + FLOT vs. FLOT Alone for Resectable Esophagogastric Adenocarcinoma With High Rate of Signet Cell Component: Final Results of the Multicenter, Randomized Phase II/III Trial
By
ASCO 2022 Conference Coverage
FEATURING
Thorsten Oliver Götze
By
ASCO 2022 Conference Coverage
FEATURING
Thorsten Oliver Götze
17 views
June 14, 2022
Comments 0
Login to view comments.
Click here to Login
GI